{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:58:43Z","timestamp":1783357123750,"version":"3.54.6"},"reference-count":99,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ecl.2025.12.002","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T21:40:17Z","timestamp":1770241217000},"page":"271-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation and Management of Primary Aldosteronism"],"prefix":"10.1016","volume":"55","author":[{"given":"St\u00e9fanie","family":"Parisien-La Salle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ecl.2025.12.002_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.ecl.2025.12.002_bib2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1161\/HYPERTENSIONAHA.121.18118","article-title":"Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: a population-based retrospective cohort study","volume":"79","author":"Hundemer","year":"2022","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.ecl.2025.12.002_bib3","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/HYPERTENSIONAHA.119.14359","article-title":"Screening rates for primary aldosteronism in resistant hypertension","volume":"75","author":"Jaffe","year":"2020","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.ecl.2025.12.002_bib4","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/1471-0528.14918","article-title":"Hormone-secreting adrenal tumours cause severe hypertension and high rates of poor pregnancy outcome; a UK obstetric surveillance system study with case control comparisons","volume":"125","author":"Quartermaine","year":"2018","journal-title":"BJOG"},{"issue":"1","key":"10.1016\/j.ecl.2025.12.002_bib5","first-page":"3","article-title":"Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome","volume":"45","author":"Conn","year":"1955","journal-title":"J Lab Clin Med"},{"issue":"9","key":"10.1016\/j.ecl.2025.12.002_bib6","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7326\/M17-0882","article-title":"The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study","volume":"167","author":"Brown","year":"2017","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.ecl.2025.12.002_bib7","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1161\/HYPERTENSIONAHA.122.19134","article-title":"Cardiac structure and function across the spectrum of aldosteronism: the atherosclerosis risk in communities study","volume":"79","author":"Brown","year":"2022","journal-title":"Hypertension"},{"issue":"14","key":"10.1016\/j.ecl.2025.12.002_bib8","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","article-title":"Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension","volume":"393","author":"Flack","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ecl.2025.12.002_bib9","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1210\/jc.2016-3867","article-title":"Renin phenotypes characterize vascular disease, autonomous aldosteronism, and mineralocorticoid receptor activity","volume":"102","author":"Hundemer","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2025.12.002_bib10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/HYPERTENSIONAHA.124.24137","article-title":"Closing the gap in global disparities in hypertension control","volume":"82","author":"Mishra","year":"2025","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.ecl.2025.12.002_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033253","article-title":"Hypertension trends and disparities over 12 years in a large health system: leveraging the electronic health records","volume":"13","author":"Brush","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"38","key":"10.1016\/j.ecl.2025.12.002_bib12","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"issue":"10258","key":"10.1016\/j.ecl.2025.12.002_bib13","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ecl.2025.12.002_bib14","doi-asserted-by":"crossref","first-page":"e1280","DOI":"10.1210\/clinem\/dgad654","article-title":"Time to benefit of surgery vs targeted medical therapy for patients with primary aldosteronism: a meta-analysis","volume":"109","author":"Samnani","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ecl.2025.12.002_bib15","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1210\/clinem\/dgae145","article-title":"The spectrum of dysregulated aldosterone production: an international human physiology study","volume":"109","author":"Parksook","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2025.12.002_bib16","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.mce.2016.10.014","article-title":"Immunohistochemistry of aldosterone synthase leads the way to the pathogenesis of primary aldosteronism","volume":"441","author":"Nishimoto","year":"2017","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2025.12.002_bib17","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/HYPERTENSIONAHA.118.11086","article-title":"Cellular and genetic causes of idiopathic hyperaldosteronism","volume":"72","author":"Omata","year":"2018","journal-title":"Hypertension"},{"issue":"1\u20132","key":"10.1016\/j.ecl.2025.12.002_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.mce.2013.11.022","article-title":"Development of monoclonal antibodies against human CYP11B1 and CYP11B2","volume":"383","author":"Gomez-Sanchez","year":"2014","journal-title":"Mol Cell Endocrinol"},{"issue":"7","key":"10.1016\/j.ecl.2025.12.002_bib19","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1210\/js.2017-00134","article-title":"Aldosterone-producing cell clusters frequently harbor somatic mutations and accumulate with age in normal adrenals","volume":"1","author":"Omata","year":"2017","journal-title":"J Endocr Soc"},{"issue":"33","key":"10.1016\/j.ecl.2025.12.002_bib20","doi-asserted-by":"crossref","first-page":"E4591","DOI":"10.1073\/pnas.1505529112","article-title":"Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands","volume":"112","author":"Nishimoto","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ecl.2025.12.002_bib21","article-title":"Is it time to retire confirmatory testing for primary aldosteronism?","author":"Kline","year":"2025","journal-title":"Am J Hypertens"},{"issue":"6","key":"10.1016\/j.ecl.2025.12.002_bib22","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1210\/er.2018-00139","article-title":"The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr Rev"},{"issue":"11","key":"10.1016\/j.ecl.2025.12.002_bib23","doi-asserted-by":"crossref","first-page":"e3832","DOI":"10.1210\/clinem\/dgaf129","article-title":"Subclinical primary aldosteronism is characterized by maladaptive natriuretic peptide and adrenal hormonal physiology","volume":"110","author":"Parisien-La Salle","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2025.12.002_bib24","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/HYPERTENSIONAHA.116.08952","article-title":"Continuum of renin-independent aldosteronism in normotension","volume":"69","author":"Baudrand","year":"2017","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.ecl.2025.12.002_bib25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.123.066389","article-title":"Subclinical primary aldosteronism and cardiovascular health: a population-based cohort study","volume":"149","author":"Hundemer","year":"2024","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ecl.2025.12.002_bib26","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1210\/jc.2012-3353","article-title":"Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension","volume":"98","author":"Markou","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"10.1016\/j.ecl.2025.12.002_bib27","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.ecl.2025.12.002_bib28","doi-asserted-by":"crossref","first-page":"408","DOI":"10.5694\/mja2.51438","article-title":"Detecting primary aldosteronism in Australian primary care: a prospective study","volume":"216","author":"Libianto","year":"2022","journal-title":"Med J Aust"},{"issue":"7","key":"10.1016\/j.ecl.2025.12.002_bib29","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1210\/jc.2016-1472","article-title":"Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis","volume":"101","author":"K\u00e4yser","year":"2016","journal-title":"J Clin Endocrinol Metabol"},{"issue":"12","key":"10.1016\/j.ecl.2025.12.002_bib30","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1055\/s-0043-119755","article-title":"Is primary aldosteronism still largely unrecognized?","volume":"49","author":"Buffolo","year":"2017","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.ecl.2025.12.002_bib31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-042711-135929","article-title":"Hyperaldosteronism as a common cause of resistant hypertension","volume":"64","author":"Calhoun","year":"2013","journal-title":"Annu Rev Med"},{"issue":"9628","key":"10.1016\/j.ecl.2025.12.002_bib32","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(08)60834-X","article-title":"Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study","volume":"371","author":"Douma","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ecl.2025.12.002_bib33","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1161\/HYPERTENSIONAHA.119.14063","article-title":"Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit","volume":"75","author":"Burrello","year":"2020","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.ecl.2025.12.002_bib34","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/HJH.0000000000002250","article-title":"Atrial fibrillation as presenting sign of primary aldosteronism: results of the prospective appraisal on the prevalence of primary aldosteronism in hypertensive (PAPPHY) study","volume":"38","author":"Seccia","year":"2020","journal-title":"J Hypertens"},{"issue":"1","key":"10.1016\/j.ecl.2025.12.002_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2025.12.002_bib36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2025.12.002_bib37","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s12020-021-02704-2","article-title":"Higher risk of chronic kidney disease and progressive kidney function impairment in primary aldosteronism than in essential hypertension. Case-control study","volume":"73","author":"Fern\u00e1ndez-Arg\u00fceso","year":"2021","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.ecl.2025.12.002_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HJH.0000000000002216","article-title":"Renal damage in primary aldosteronism: a systematic review and meta-analysis","volume":"38","author":"Monticone","year":"2020","journal-title":"J Hypertens"},{"issue":"3","key":"10.1016\/j.ecl.2025.12.002_bib39","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","article-title":"Renal outcomes in medically and surgically treated primary aldosteronism","volume":"72","author":"Hundemer","year":"2018","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.ecl.2025.12.002_bib40","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1055\/a-1134-4980","article-title":"Hypokalemia and the prevalence of primary aldosteronism","volume":"52","author":"Gruber","year":"2020","journal-title":"Horm Metab Res"},{"issue":"10","key":"10.1016\/j.ecl.2025.12.002_bib41","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1210\/clinem\/dgae415","article-title":"The prevalence of obstructive sleep apnea in patients with primary aldosteronism","volume":"109","author":"Sheu","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2025.12.002_bib42","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1055\/a-1133-7255","article-title":"Primary aldosteronism and obstructive sleep apnea: casual association or pathophysiological link?","volume":"52","author":"Pecori","year":"2020","journal-title":"Horm Metab Res"},{"issue":"9","key":"10.1016\/j.ecl.2025.12.002_bib43","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary aldosteronism: an endocrine society clinical practice guideline","volume":"110","author":"Adler","year":"2025","journal-title":"J Clin Endocrinol Metabol"},{"issue":"4","key":"10.1016\/j.ecl.2025.12.002_bib44","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1507\/endocrj.EJ21-0508","article-title":"Japan endocrine society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021","volume":"69","author":"Naruse","year":"2022","journal-title":"Endocr J"},{"issue":"11","key":"10.1016\/j.ecl.2025.12.002_bib45","first-page":"e114","volume":"152","author":"Jones","year":"2025","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ecl.2025.12.002_bib46","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metabol"},{"issue":"4","key":"10.1016\/j.ecl.2025.12.002_bib47","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMimc2401927","article-title":"Targeting a hormonal cause of hypertension","volume":"392","author":"Vaidya","year":"2025","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ecl.2025.12.002_bib48","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.jacc.2025.08.014","article-title":"Primary aldosteronism: ubiquitous, yet unrecognized","volume":"86","author":"Brown","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.ecl.2025.12.002_bib49","doi-asserted-by":"crossref","first-page":"948","DOI":"10.7326\/ANNALS-24-03153","article-title":"Confirmatory testing for primary aldosteronism : a study of diagnostic test accuracy","volume":"178","author":"Leung","year":"2025","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.ecl.2025.12.002_bib50","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/ejendo\/lvaf170","article-title":"Discordance and shortcomings of aldosterone suppression tests in primary aldosteronism","volume":"193","author":"Tsai","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ecl.2025.12.002_bib51","first-page":"hpaf156","article-title":"Rethinking primary aldosteronism: the 2025 john H. Laragh research award","author":"Hundemer","year":"2025","journal-title":"Am J Hypertens"},{"issue":"8","key":"10.1016\/j.ecl.2025.12.002_bib52","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1161\/HYPERTENSIONAHA.122.19377","article-title":"Performance of confirmatory tests for diagnosing primary aldosteronism: a systematic review and meta-analysis","volume":"79","author":"Leung","year":"2022","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.ecl.2025.12.002_bib53","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/HYPERTENSIONAHA.125.24711","article-title":"ACE inhibition to distinguish low-renin hypertension from primary aldosteronism","volume":"82","author":"Tsai","year":"2025","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.ecl.2025.12.002_bib54","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/HYPERTENSIONAHA.116.07214","article-title":"Suppression of aldosterone secretion after recumbent saline infusion does not exclude lateralized primary aldosteronism","volume":"68","author":"Cornu","year":"2016","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.ecl.2025.12.002_bib55","doi-asserted-by":"crossref","DOI":"10.1111\/jch.70062","article-title":"LC-MS\/MS-based assay for steroid profiling in peripheral and adrenal venous samples for the subtyping of primary aldosteronism","volume":"27","author":"Chen","year":"2025","journal-title":"J Clin Hypertens"},{"issue":"9","key":"10.1016\/j.ecl.2025.12.002_bib56","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.16209","article-title":"Use of steroid profiling combined with machine learning for identification and subtype classification in primary aldosteronism","volume":"3","author":"Eisenhofer","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ecl.2025.12.002_bib57","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1161\/HYPERTENSIONAHA.119.13866","article-title":"Comprehensive analysis of steroid biomarkers for guiding primary aldosteronism subtyping","volume":"75","author":"Turcu","year":"2020","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.ecl.2025.12.002_bib58","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1055\/a-1141-3526","article-title":"Developments in primary aldosteronism subtyping using steroid profiling","volume":"52","author":"Wannachalee","year":"2020","journal-title":"Horm Metab Res"},{"issue":"4","key":"10.1016\/j.ecl.2025.12.002_bib59","doi-asserted-by":"crossref","first-page":"e1363","DOI":"10.1210\/clinem\/dgad542","article-title":"The promise of nuclear imaging as an alternative to adrenal venous sampling for the detection of aldosterone-producing adenomas","volume":"109","author":"Vaidya","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2025.12.002_bib60","doi-asserted-by":"crossref","first-page":"336","DOI":"10.7326\/ANNALS-24-00761","article-title":"Molecular imaging versus adrenal vein sampling for the detection of surgically curable primary aldosteronism : a prospective within-patient trial","volume":"178","author":"Goodchild","year":"2025","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.ecl.2025.12.002_bib61","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/HJH.0000000000003132","article-title":"11C-Metomidate PET-CT versus adrenal vein sampling to subtype primary aldosteronism: a prospective clinical trial","volume":"40","author":"Puar","year":"2022","journal-title":"J Hypertens"},{"issue":"2","key":"10.1016\/j.ecl.2025.12.002_bib62","doi-asserted-by":"crossref","first-page":"e2255609","DOI":"10.1001\/jamanetworkopen.2022.55609","article-title":"Accuracy of gallium-68 pentixafor positron emission tomography\u2013computed tomography for subtyping diagnosis of primary aldosteronism","volume":"6","author":"Hu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ecl.2025.12.002_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.surg.2025.109156","article-title":"Evaluating the value of chemokine receptor type 4-targeted PET imaging in diagnosing primary aldosteronism lateralization: a comparison with adrenal venous sampling","volume":"181","author":"Lu","year":"2025","journal-title":"Surgery"},{"issue":"Supplement_1","key":"10.1016\/j.ecl.2025.12.002_bib64","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae163.580","article-title":"7974 expression of C-X-C motif chemokine receptor 4 (CXCR4) in aldosterone-producing adenomas and adjacent non-functional adenomas","volume":"8","author":"Wu","year":"2024","journal-title":"Journal of the Endocrine Society"},{"issue":"13","key":"10.1016\/j.ecl.2025.12.002_bib65","doi-asserted-by":"crossref","first-page":"9321","DOI":"10.1021\/acs.jmedchem.1c00539","article-title":"Development of [(18)F]Aldoview as the first highly selective aldosterone synthase PET tracer for imaging of primary hyperaldosteronism","volume":"64","author":"Sander","year":"2021","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.ecl.2025.12.002_bib66","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/RLU.0000000000006014","article-title":"First-in-Human evaluation of [ 18 F]AldoView: a highly selective PET tracer for aldosterone synthase imaging in primary aldosteronism","volume":"50","author":"Long","year":"2025","journal-title":"Clin Nucl Med"},{"issue":"11","key":"10.1016\/j.ecl.2025.12.002_bib67","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1210\/jc.2016-1963","article-title":"Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism","volume":"101","author":"Baudrand","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2025.12.002_bib68","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/HYPERTENSIONAHA.116.07615","article-title":"Dietary salt intake is a determinant of cardiac changes after treatment of primary aldosteronism: a prospective study","volume":"68","author":"Catena","year":"2016","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.ecl.2025.12.002_bib69","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1210\/jc.2011-0354","article-title":"Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study","volume":"96","author":"Pimenta","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2025.12.002_bib70","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/joim.13618","article-title":"Moderate dietary salt restriction improves blood pressure and mental well-being in patients with primary aldosteronism: the salt CONNtrol trial","volume":"294","author":"Schneider","year":"2023","journal-title":"J Intern Med"},{"issue":"9","key":"10.1016\/j.ecl.2025.12.002_bib71","doi-asserted-by":"crossref","first-page":"e2833","DOI":"10.1210\/clinem\/dgaf290","article-title":"A systematic review supporting the endocrine society clinical practice guideline on management of primary aldosteronism","volume":"110","author":"Farah","year":"2025","journal-title":"J Clin Endocrinol Metabol"},{"issue":"8","key":"10.1016\/j.ecl.2025.12.002_bib72","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1161\/HYPERTENSIONAHA.125.25104","article-title":"Adrenalectomy versus medical therapy in primary aldosteronism: a meta-analysis of long-term cardiac remodeling and function: medical versus adrenalectomy treatment compared in hyperaldosteronism (MATCH) study","volume":"82","author":"Marzano","year":"2025","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.ecl.2025.12.002_bib73","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/ajh\/hpaf091","article-title":"Recent advances in adrenal ablation for primary aldosteronism","volume":"38","author":"Glassman","year":"2025","journal-title":"Am J Hypertens"},{"issue":"9","key":"10.1016\/j.ecl.2025.12.002_bib74","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/ajh\/hpaf029","article-title":"Comparative outcomes of adrenalectomy, mineralocorticoid receptor antagonist, and percutaneous adrenal ablation for primary aldosteronism: a systematic review and network meta-analysis","volume":"38","author":"Yuan","year":"2025","journal-title":"Am J Hypertens"},{"issue":"7","key":"10.1016\/j.ecl.2025.12.002_bib75","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/CIRCULATIONAHA.121.054318","article-title":"Catheter-based adrenal ablation remits primary aldosteronism: a randomized medication-controlled trial","volume":"144","author":"Zhao","year":"2021","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ecl.2025.12.002_bib76","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1148\/radiol.2016152277","article-title":"Aldosterone-producing adenoma in primary aldosteronism: CT-guided radiofrequency ablation-long-term results and recurrence rate","volume":"281","author":"Liu","year":"2016","journal-title":"Radiology"},{"issue":"7","key":"10.1016\/j.ecl.2025.12.002_bib77","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jvir.2016.03.042","article-title":"Clinical outcomes following percutaneous radiofrequency ablation of unilateral aldosterone-producing adenoma: comparison with adrenalectomy","volume":"27","author":"Sarwar","year":"2016","journal-title":"J Vasc Intervent Radiol"},{"issue":"9","key":"10.1016\/j.ecl.2025.12.002_bib78","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/jch.13960","article-title":"Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma: an efficacy and safety, proof-of-principle trial","volume":"22","author":"Zhang","year":"2020","journal-title":"J Clin Hypertens"},{"issue":"1","key":"10.1016\/j.ecl.2025.12.002_bib79","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41440-022-01034-8","article-title":"Catheter-based adrenal ablation: an alternative therapy for patients with aldosterone-producing adenoma","volume":"46","author":"Sun","year":"2023","journal-title":"Hypertens Res"},{"issue":"2","key":"10.1016\/j.ecl.2025.12.002_bib80","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-131-2-199907200-00005","article-title":"Medical management of aldosterone-producing adenomas","volume":"131","author":"Ghose","year":"1999","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.ecl.2025.12.002_bib81","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1046\/j.1365-2125.1999.00070.x","article-title":"Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study","volume":"48","author":"Lim","year":"1999","journal-title":"Br J Clin Pharmacol"},{"issue":"13","key":"10.1016\/j.ecl.2025.12.002_bib82","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023813","article-title":"Comparison of echocardiographic changes between surgery and medication treatment in patients with primary aldosteronism","volume":"11","author":"Ueda","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ecl.2025.12.002_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.916744","article-title":"Treatment of primary aldosteronism and reversal of renin suppression improves left ventricular systolic function","volume":"13","author":"Puar","year":"2022","journal-title":"Front Endocrinol"},{"issue":"8","key":"10.1016\/j.ecl.2025.12.002_bib84","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1001\/jamacardio.2018.2003","article-title":"Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism","volume":"3","author":"Hundemer","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"9","key":"10.1016\/j.ecl.2025.12.002_bib85","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1161\/HYPERTENSIONAHA.123.21096","article-title":"Association of reversal of renin suppression with long-term renal outcome in medically treated primary aldosteronism","volume":"80","author":"Katsuragawa","year":"2023","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.ecl.2025.12.002_bib86","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-21-0836","article-title":"Long-term mortality and cardiovascular events in patients with unilateral primary aldosteronism after targeted treatments","volume":"186","author":"Wu","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2025.12.002_bib87","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1210\/endrev\/bnad024","article-title":"Biomarkers to guide medical therapy in primary aldosteronism","volume":"45","author":"Hundemer","year":"2024","journal-title":"Endocr Rev"},{"issue":"12","key":"10.1016\/j.ecl.2025.12.002_bib88","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrneph.2012.217","article-title":"Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy","volume":"8","author":"Roscioni","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"16","key":"10.1016\/j.ecl.2025.12.002_bib89","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ecl.2025.12.002_bib90","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ecl.2025.12.002_bib91","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ecl.2025.12.002_bib92","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1111\/bph.15747","article-title":"Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"179","author":"Kintscher","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.ecl.2025.12.002_bib93","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1161\/CIRCULATIONAHA.124.071452","article-title":"Efficacy and safety of finerenone in patients with primary aldosteronism: a pilot randomized controlled trial","volume":"151","author":"Hu","year":"2025","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ecl.2025.12.002_bib94","doi-asserted-by":"crossref","first-page":"K50","DOI":"10.1093\/ejendo\/lvaf099","article-title":"Real-world outcomes of finerenone in primary aldosteronism","volume":"192","author":"Uslar","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"14","key":"10.1016\/j.ecl.2025.12.002_bib95","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMe2511533","article-title":"Aldosterone synthase inhibition for hypertension","volume":"393","author":"Guzik","year":"2025","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ecl.2025.12.002_bib96","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the target-htn randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.ecl.2025.12.002_bib97","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","article-title":"Lorundrostat efficacy and safety in patients with uncontrolled hypertension","volume":"392","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ecl.2025.12.002_bib98","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ecl.2025.12.002_bib99","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1056\/NEJMc2508629","article-title":"Phase 2a study of baxdrostat in primary aldosteronism","volume":"393","author":"Turcu","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925001057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925001057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:52:02Z","timestamp":1781621522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852925001057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":99,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0889852925001057"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2025.12.002","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation and Management of Primary Aldosteronism","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2025.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}